Member Info for DiscoDividends

Also states - "A strong positive outcome would imply 149p share price"

Summary of the Liberum note - Futura is set to report headline data from its P3 FM57 study in erectile dysfunction (ED) in December. We believe that the trial is significantly de-risked and hence estimate a >70% probability of some form of positive outcome.

Not working for me I'm afraid.

Chariot - link won't work.

Just released - https://www.trinitydelta.org/companies/futura-medical/

So tempting to top up more and more.

Anyone else topping up?

C&D indeed did run with it for a (very) short period of time, but had a revised their business strategy and decided to abort all non-core products. FUM's CSD500 was one of those casualties.

I'll be capitalizing on any dips in SP - so no bad thing in the short term. :-)

I believe w/c 16th Dec would be the ideal timing. Jefferies Healthcare conference is this week in London and I am certain deal-making discussions will be in full flow for FUM. I agree that likely the full jump in SP (>£1) will be post Ph III results, not before. Currently, still a buy in my eyes and may top up in the event of any dips in price before then.

Thanks for proving my point TB. Go take your pills and calm down.

I've got my stack of FUM shares and will sit quietly aside whilst you continue to wind others up.

TB just STFU will you... Christ! Keep it simple, straight forward and business only. Stopping calling people out and vice versa.

We're all here for good trades. NO BS.

This chat needs a BS filter. Keep it business folks.

Nice move. I should have done it yesterday but too but acquired an additional 25k shares this morning and will continue to buy as confidence builds even further.

I've backed up my position with a strong buy this morning. No BS just actions. GLA

New CEO appointed and new NED. RNS live

One could argue you doing the opposite. Causing sell pressure so you can snap up cheap shares...

You guys have too much time on yours hands.

Long term lurker. Know enough about the Life Science, Healthcare and Consumer Health space to make me dangerous.

I am confident the share price will see a turnaround. There is still a lot to be done and a fair way to go, but the Board and Chairman combined with a very sound technology offering with a strong clinical and consumer utility, gives me a great deal of confidence. I know the fertility and diagnostic market well.

I believe these recent lows are a floor and we should see a steady creep in price in the right direction. As said, plenty still to do, but headed in the right direction. Top line sales will come, that is for sure.